A phase II study in patients with Non-Alcoholic Fatty Liver Diseases (NAFLD) has been initiated
ScandiBio Therapeutics has initiated a Phase II study in patients with Non-Alcoholic Fatty Liver Diseases (NAFLD) using Combined Metabolic Cofactors Supplementation (CMCS) consisting of L-serine, N-acetyl-L-cysteine…